Nurix Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
We'll kick things off here with the last fireside chat session of the day here. But thanks, everybody, for joining us here at Piper Sandler's Annual Healthcare Conference. I'm Joe Catanzaro from the Piper biotech research team. It's my real pleasure to welcome Nurix Therapeutics and their CEO, Arthur Sands. Arthur, thanks so much for making the time here.
Obviously, you guys have a ton going on, and a ton to talk about here in a short 25 minutes. But maybe first, I can give you a sort of brief window here to just give a rundown of Nurix, and what you guys have been up to, and what we have to look forward to.
Certainly. And thanks, Joe, for having us. So, Nurix, we have four programs in the clinic now in oncology, in leukemia and lymphomas, and also in solid tumors. So, we indeed have a lot of programs to keep updating everyone on, and we appreciate the opportunity.
We create small molecules that modulate protein levels. So,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |